ZAP Surgical Receives Regulatory Approval in India for Its First ZAP-X Gyroscopic Radiosurgery Platform

Approval Expands Access to Completely Non-Invasive Treatment of Brain Tumors

SAN CARLOS, Calif.–(BUSINESS WIRE)–ZAP Surgical Systems, Inc. today announced that the company received regulatory approval in India for its first ZAP-X® Gyroscopic Radiosurgery® platform in the form of a No Objection Certificate (NOC) from the Atomic Energy Regulatory Board (AERB).


Radiosurgery, also commonly referred to as SRS, is well recognized as a non-invasive alternative to surgery for effectively treating many brain tumors, including brain metastases and functional disease. Unique from surgery, however, radiosurgical procedures require no incision, are painless, and patients often immediately return to normal activities.

With NOC approval in India, ZAP is one step closer to bringing the benefits of SRS to a broader worldwide population of patients. To this end, the company has opened a ZAP office located in Gurgaon, India to oversee the further market penetration and commercialization of its novel radiosurgery system.

“At ZAP, our mission is to expand world-class SRS access to the millions of potential patients who currently lack access throughout the world,” said Saloni Singh, Country Head of India at ZAP Surgical. “By reducing the costs and complexities of prior delivery technologies, ZAP-X is enabling broader adoption of such technology and is primed to make a significant impact on patient care in India.”

The ZAP-X system is the latest advance in stereotactic radiosurgery in nearly half a century. Unlike all historical technologies, ZAP introduced the concept of vault-free SRS which eliminates the need for costly radiation-proof treatment bunkers. Additionally, by removing the historical need to host volatile live radioactive isotopes, ZAP-X removes the effort and expense associated with continued source decay, recurring replacement, as well as regulatory licensing and source security.

“By introducing leading-edge innovations such as self-shielding and a modern linear accelerator, ZAP-X has removed many of the financial and logistical constraints that previously prohibited centers from acquiring SRS technology,” said Ahmed Salem, IMEA Regional Business Director at ZAP Surgical. “Where state-of-the-art SRS has historically been concentrated primarily amongst the most well-funded, urban academic hospitals, ZAP-X now makes SRS also feasible in suburban and rural settings – thus bringing potentially life-saving care to previously underserved populations.”

Learn more at ZAP Surgical and follow us on LinkedIn and Twitter. Detailed system videos can be found on ZAP Surgical’s YouTube page.

About ZAP Surgical Systems, Inc.

ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgery® platform. ZAP was founded in 2014 by Dr. John R. Adler. In addition to being CEO of ZAP, Dr. Adler is Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. Dr. Adler is also renowned as the inventor of the CyberKnife® system and founder of Accuray, Inc. The ZAP-X platform incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. ZAP-X also utilizes a modern linear accelerator to eliminate legacy use of Cobalt-60.

Contacts

Mark Arnold, ZAP Surgical Systems, Inc.

Senior Vice President, Marketing

+1 650 492 7797, ext. 101

Email: [email protected]

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.